Research
Hormonal
Replacing saturated fatty acids with monounsaturated (MUFA) and polyunsaturated fatty acids (PUFA) improves glycemic control and reduces cardiovascular risk in type 2 diabetes patients.
Focus on the quality of fats you eat. Replace butter, lard, and fatty meats with olive oil, nuts, seeds, and fish. This substitution helps your body use insulin better and protects your heart.
GoodSupportsHIGH confidence
Recent studies have found strong evidence on the beneficial effects of dietary polyunsaturated fatty acids... solid evidence of improvement in glycemic control and reduction of the risk of cardiovascular events when saturated fatty acids intake is replaced by PUFA intake.
Why this rating
Based on a review of 13 studies including RCTs and prospective cohorts, though the review itself is not a meta-analysis.
Source
Unsaturated fatty acid as functional food for the treatment of Diabetes mellitus type 2
Naiane Silva Cardoso et al. · Research Society and Development · 2021
DOI 10.33448/rsd-v10i9.17231
narrative_reviewCited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Monounsaturated fatty acids (MUFA) preserve insulin signaling and activate AMPK, while polyunsaturated fatty acids (PUFA) increase GLUT4 expression and mitochondrial function.Good
- High egg intake (up to 12 eggs/week) does not significantly increase cardiovascular risk, inflammatory biomarkers, or blood sugar levels in type 2 diabetic patients when part of a weight-loss diet.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →